Aim 3, Optimizing CRC Screening in Patients With Diabetes in Safety-net Primary Care Settings
Part of paid clinical trials in New Brunswick, New Jersey.
- Sponsor
- Rutgers, The State University of New Jersey
- Study ID
- NCT05785780
- Status
- Enrolling By Invitation
Conditions
- Colorectal Cancer Screening
- Diabetes Mellitus, Type 2
Eligibility Criteria
- Sex
- ALL
- Age
- 50 Years - 74 Years
- Healthy Volunteers
- Accepted
Interventions
- Targeted CRC Screening Toolkit — BEHAVIORALStrategies in the toolkit include but are not limited to: identification of patient and practice-level barriers, routine tailored patient reminders, provider reminders, \& clinic staff feedback.
Study Details
This mixed methods study evaluates the effectiveness and feasibility of a multi-level (patient, team, organizations) intervention to optimize CRC screening for patients with diabetes in primary care safety-net settings.
Key Dates
- Start date
- Nov 1, 2022
- Status verified
- May 2026
- Primary completion
- Jun 30, 2026
- Completion
- Jun 30, 2026
Study Design
- Enrollment
- 30 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- HEALTH_SERVICES_RESEARCH
Arms
- Experimental: Targeted CRC Screening ToolkitBased on national survey data and a community engagement participatory implemention planning group, a tailored combination of widely accepted implementation strategies will be adapted for targeting CRC screening for patients with diabetes. These strategies include but are not limited to: identification of patient and practice-level barriers, patient education, provider reminders, and audit and feedback.
Primary Outcome Measure
Colonoscopy uptake [ Time Frame: 12 months ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| RWJBarnabas Health - Robert Wood Johnson University Hospital | New Brunswick | New Jersey | 08903 | - |
Find similar trials in New Brunswick, NJ
By condition
By specialty
Related Studies
- A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular EventsRecruiting · Cleerly, Inc. · Chandler, Arizona
- Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II DiabetesRecruiting · Endogenex, Inc. · Birmingham, Alabama
- EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular DiseasePHASE3 · Recruiting · Boehringer Ingelheim · Anniston, Alabama
- A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 DiabetesPHASE2 · Recruiting · Eli Lilly and Company · Gilbert, Arizona